Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

This study has been completed.

Sponsor:

Collaborator:

Genentech, Inc.

Information provided by:

New York University School of Medicine

ClinicalTrials.gov Identifier:

NCT00134134

First received: August 23, 2005

Last updated: September 7, 2006

Last verified: September 2006

History of Changes

Purpose

The purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa, and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab, after the medication is stopped.

Condition	Intervention	Phase
Hidradenitis Suppurativa	Drug: efalizumab	Phase 1


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa

Resource links provided by NLM:

Genetics Home Reference related topics: hidradenitis suppurativa

MedlinePlus related topics: Hidradenitis Suppurativa

U.S. FDA Resources

Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:

Reduction in number of inflammatory lesions 12 weeks post-baseline

Secondary Outcome Measures:

Time to the reduction of lesions during 12 weeks of treatment
Percent of disease activity at various weeks after baseline


Estimated Enrollment:	5
Study Start Date:	February 2005
Estimated Study Completion Date:	August 2006

Detailed Description:

The primary objective of this study is to assess the efficacy of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa. The secondary objectives of this study are to assess the ability to re-establish disease control after discontinuation of drug and allowance for relapse of disease, as well as to assess the safety of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Female between 18-65 years of age
Has Hydradenitis Suppurativa (HS) involving at least 1 area of the body with greater than or equal to 12 lesions; onset of disease is 6 months and greater.
Failed at least 3 months of standard conventional therapies such as antibiotics and/or systemic retinoids
Willing to use contraception unless not of childbearing potential
Able to comply with protocol requirements

Exclusion Criteria:

Received within 4 weeks prior immunosuppressive medication
Received treatment within 3 months prior with systemic retinoids (acitretin or isotretinoin)
Received high potency (class I or II) topical corticoid steroids, topical antibiotics, systemic antibiotics, or topical immunomodulators (tacrolimus or pimecrolimus) within 2 weeks prior to baseline visit
Received intralesional injections of corticosteroids within 4 weeks prior
Received surgical intervention for the treatment of HS
Known history of HIV seropositivity
History of untreated or active tuberculosis
Active infection requiring systemic antibiotics within 4 weeks of baseline visit
History of recurrent/chronic infections
History of malignancy within 5 years of baseline visit (except for squamous cell carcinoma or basal cell carcinoma; may enroll if treated and assessed as cured).
Pregnant or breastfeeding
Immunocompromised due to a medical condition
Has any significant laboratory abnormalities
Has any medical condition that may interfere with evaluation of the safety and efficacy of efalizumab
Received efalizumab or any other biologic within the last 6 months
Taken or used any investigational drug or device within 30 days prior

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00134134

Locations


United States, New York
New York University School of Medicine, Dept of Dermatology
New York, New York, United States, 10016

Sponsors and Collaborators

New York University School of Medicine

Genentech, Inc.

Investigators


Principal Investigator:	Bruce Strober, MD, PhD	New York University School of Medicine

More Information


ClinicalTrials.gov Identifier:	NCT00134134 History of Changes
Other Study ID Numbers:	H12452-01B
Study First Received:	August 23, 2005
Last Updated:	September 7, 2006

Keywords provided by New York University School of Medicine:


hidradenitis suppurativa efalizumab biologic Raptiva

Additional relevant MeSH terms:


Hidradenitis Hidradenitis Suppurativa Sweat Gland Diseases Skin Diseases Skin Diseases, Bacterial Bacterial Infections	Skin Diseases, Infectious Infection Suppuration Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 23, 2017

To Top